TREATMENT OF PREMATURE BIRTH COMPLICATIONS

• US 20090136471A1
• Filed: 11/07/2008
• Published: 05/28/2009
• Est. Priority Date: 11/07/2007
• Status: Abandoned Application

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Johnson, Kristine Erickson, Hariri, Robert J., Heidaran, Mohammad A.
• Application Number:
  US12/267,499
• Publication Number:
  US 20090136471A1
• Time in Patent Office: Days
• US Class Current: 424/93.730
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/714 Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 35/18 Erythrocytes haemoglobin A61K38/42
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/02 : Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention provides methods of treating one or more complications of premature birth suffered by premature infants, comprising administering to the premature infant umbilical cord blood stem cells and, optionally, placental stem cells. The present invention also provides methods of combining and administering, and compositions comprising, umbilical cord blood stem cells, particularly autologous cord blood cells, and placental stem cells for the treatment of premature infants.

Claims

1. A method of treating a disorder or condition of a premature infant, comprising administering to said premature infant umbilical cord blood, wherein said disorder or condition is caused by or associated with premature birth.

2. The method of claim 1 further comprising administering placental stem cells to the premature infant.

3. The method of claim 1 further comprising administering a blood additive, wherein said blood additive is erythropoietin, an iron supplement, a vitamin, or red blood cells from a source other than cord blood.

4. The method of claim 1, wherein said premature infant has undergone from about 23 to about 37 weeks of gestation at birth.

5. The method of claim 1, wherein said disorder or condition is selected from the group consisting of Respiratory Distress Syndrome (RDS), Acute Respiratory Distress Syndrome (ARDS), anemia, a neurological deficiency, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, chronic lung disease (bronchopulmonary dysplasia), an infection, patent ductus arteriosus, apnea, low blood pressure, and hyperbilirubinemia.

6. The method of claim 1, wherein said disorder or condition is caused by incomplete development of an organ.

7. The method of claim 1, wherein said umbilical cord blood is autologous to the premature infant.

8. The method of claim 2, wherein the placental stem cells are autologous to the premature infant.

9. The method of claim 1, wherein said umbilical cord blood is obtained from a cord blood bank.

10. The method of claim 2, wherein said placental stem cells are stem cells isolated from placental perfusate prior to said administering.

11. The method of claim 2, wherein said placental stem cells are stem cells contained within placental perfusate.

12. The method of claim 2, wherein said placental stem cells comprise:

a. CD34⁻

;

b. OCT-4⁺;

c. CD200⁺ and HLA-G⁺;

d. CD73⁺, CD105⁺, and CD200⁺;

e. CD200⁺ and OCT-4⁺;

f. CD73⁺, CD105⁺ and HLA-G⁺;

g. CD73⁺ and CD105⁺ and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising said stem cell when said population is cultured under conditions that allow the formation of an embryoid-like body;

or

h. OCT-4⁺ and facilitate the formation of one or more embryoid-like bodies in a population of placental cells comprising the stem cell when said population is cultured under conditions that allow formation of embryoid-like bodies;

or any combination thereof.

13. The method of claim 2, wherein said placental stem cells comprise CD34⁺ cells.

14. The method of claim 1, wherein said administering is performed once after birth of the premature infant.

15. The method of claim 1, wherein said administering is performed a plurality of times after birth of the premature infant.

16. The method of claim 1, wherein said administering is performed within one hour, 12 hours, 24 hours, or one week after birth of the premature infant.

17. The method of claim 1, wherein said umbilical cord blood comprises about 1×

10⁵ to about 1×

10⁶ CD34⁺ cells per kilogram body weight of said premature infant.

18. The method of claim 2, wherein said placental stem cells and said umbilical cord blood together comprises about 1×

10⁵ to about 1×

10⁶ CD34⁺ cells per kilogram body weight of said premature infant.

19. The method of claim 1, wherein said administration is by intravenous injection.